Find uplifting stories about heroes, innovations, and solutions
22 results for "psychedelic therapy"
The Department of Veterans Affairs is testing MDMA-assisted therapy to treat veterans struggling with both PTSD and alcohol addiction, marking a new chapter in mental health care. This trial joins 19 other VA studies exploring how psychedelic treatments could help those traditional methods haven't reached.
A new AI platform called Lucy is solving a critical shortage in psychedelic therapy by training facilitators using real-world data from thousands of support calls. Built from a database of actual psychedelic experiences, Lucy helps prepare therapists for the emotional challenges of guiding patients through breakthrough mental health treatments.
A breakthrough treatment using psilocybin-assisted therapy is nearing FDA approval, offering hope to millions with treatment-resistant depression and PTSD. After decades without new psychiatric treatments, this could revolutionize how we heal mental illness.
A groundbreaking trial shows military veterans experiencing dramatic improvements in PTSD symptoms after just one session with ibogaine, a powerful natural psychedelic. The research could open new doors for millions struggling with treatment-resistant trauma.
A sweeping executive order is accelerating psychedelic research for mental health treatment, unlocking funding and pathways that researchers have sought for years. The question now: Can scientists deliver on the promise fast enough to help those in crisis?
The FDA is accelerating breakthrough psychedelic therapies for treatment-resistant depression, PTSD, and alcohol use disorder after a presidential directive. Veterans and millions struggling with serious mental illness could gain access to promising new options backed by rigorous science.
The Justice Department moved state-licensed medical marijuana from Schedule I to Schedule III, opening doors for research and expanded treatment options. Veterans and patients with mental health conditions could benefit most from the policy shift.
A new federal program is investing nearly $140 million to develop objective measurements for mental health treatments, helping doctors know which therapies will work for each patient before they begin. The initiative aims to end trial-and-error approaches that have left millions struggling to find effective care.
A new executive order accelerates research into psychedelic medicines for mental illness, prioritizing veterans facing treatment-resistant PTSD and depression. The move ends decades of federal prohibition and could offer hope to the 17 veterans who die by suicide every day.
President Trump signed an executive order to speed up research and potential FDA approval of psychedelic therapies for veterans suffering from PTSD, depression, and addiction. While the move brings hope to those who've exhausted traditional treatments, experts emphasize these therapies still need rigorous testing in controlled settings.
President Trump signed an executive order directing the FDA to expedite review of psychedelic drugs showing promise for veterans suffering from PTSD, depression, and traumatic brain injuries. One treatment already shows an 80-90% reduction in symptoms within one month.
President Trump signed an executive order directing federal agencies to speed up approval of psychedelic therapies for PTSD, backed by $50 million in new research funding. The move could bring relief to millions of veterans and trauma survivors as soon as this summer.
President Trump signed an executive order to speed FDA review of psychedelic treatments showing 80-90% reduction in PTSD symptoms among veterans. The breakthrough therapy could help over 6,000 veterans who die by suicide each year.
Scientists discovered that a single dose of the psychedelic compound DMT produces longer-lasting antidepressant effects in mice than the currently approved rapid-acting treatment S-ketamine. This breakthrough could offer new hope for millions struggling with treatment-resistant depression.
Researchers engineered a single tobacco plant to produce five therapeutic psychedelic compounds, creating a sustainable alternative to harvesting endangered toads and mushrooms. This biological factory could revolutionize mental health treatment access.
Scientists engineered a new version of the psychedelic compound from magic mushrooms that fights depression without causing hallucinations. Early tests in mice show the modified drug delivers brain benefits while dramatically reducing mind-altering effects.
A groundbreaking clinical trial shows one dose of the psychedelic DMT significantly reduced depression symptoms for up to six months. For millions who haven't found relief from traditional treatments, this research opens a promising new door.
A groundbreaking psilocybin-based therapy just moved closer to becoming the first psychedelic treatment approved for severe depression. Two major clinical trials showed the therapy significantly improved symptoms with just one or two doses.
A groundbreaking depression treatment using psilocybin is showing promising results in clinical trials, potentially becoming the first psychedelic therapy approved by the FDA. Two major studies confirm the compound helps patients with severe depression find relief.
A clinical trial found that one dose of DMT, a natural psychedelic compound, significantly reduced depression symptoms for up to three months. The short treatment session could make mental health care more accessible for millions who don't respond to traditional antidepressants.
Showing 20 of 22